Hualan Group (301093.SZ) subsidiary Lingqing Intelligence intends to invest in Kaimai Biotech to enter the field of AI innovative drug research and development.

Zhijong Finance and Economics APP News, Hualan Stock (301093.SZ) announced that its wholly-owned subsidiary, Lingqing Shuzhi, recently signed a capital increase agreement with Shenzhen Jingtai, XtalPi, Jingtai Zhiqi, Comai Biology, Comai Antigen, and holding platform. At the same time, Lingqing Shuzhi also signed a shareholder agreement with Shenzhen Jingtai, Comai Biology, Comai Antigen, holding platform, XtalPi, Jingtai Zhiqi, Bai'e Saitu, Duckling, and Vibrant.